ArticleClinical and vaccine immunology : CVI2011
Neutralizing activity of saliva against cytomegalovirus.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort.Science advances · 2024Article
- Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose.International journal of molecular sciences · 2022Article
- Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees.Frontiers in immunology · 2022Article
- Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis.Microorganisms · 2021Review
- Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.The Journal of infectious diseases · 2019Article
- Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.Human vaccines & immunotherapeutics · 2018Article
- Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.Clinical and vaccine immunology : CVI · 2017Article
- Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.Clinical and vaccine immunology : CVI · 2017Article
- A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.Vaccine · 2015Article
- Human cytomegalovirus: taking the strain.Medical microbiology and immunology · 2015Review
- A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.Antimicrobial agents and chemotherapy · 2015Article
- Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.Antiviral research · 2015Article
- Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.PLoS pathogens · 2014Article
- Review
- Biology and pathogenesis of cytomegalovirus in periodontal disease.Periodontology 2000 · 2014Review
- Cytomegalovirus vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Review
- Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures.Journal of virological methods · 2013Article
- Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.Clinical and vaccine immunology : CVI · 2013Article
- Alphaherpesvirinae and Gammaherpesvirinae glycoprotein L and CMV UL130 originate from chemokines.Virology journal · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Congenital cytomegalovirus (CMV) disease is the leading cause of permanent disability in neonates in the United States. Neutralizing antibodies in saliva may protect against maternal CMV infection by blocking viral entry into oral epithelial cells, but the antibody response to CMV in the saliva following natural infection is not well characterized. Saliva specimens from naturally infected individuals were tested for CMV-neutralizing activity using epithelial and fibroblast cells. Saliva from seronegative adults had no inherent anti-CMV activity. Neutralizing activity of saliva from naturally infected adults was not detectable using fibroblast cells, and saliva from young children, adolescents, and Towne vaccine recipients did not have activity using either cell type. However, when using epithelial cells, neutralizing activity was present in saliva from 50% of seropositive adults, correlated with serum-neutralizing activity, and was more prevalent in mothers of children in day care than in non-day care-associated adults. Three day care mothers with high salivary neutralizing activities (>1:20) had exceptionally high serum-neutralizing titers (3- to 8-fold higher than typical seropositives) and were immunoblot positive for serum antibodies to the epithelial entry mediator UL130. These results suggest that salivary neutralizing activities are attainable by induction of high serum IgG levels and could be utilized to evaluate candidate cytomegalovirus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.